文献速递皮肤肿瘤

布莱根妇女医院基底细胞癌T分期系统可识别转移与死亡风险患者

Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death.
PubMed 文献 · J Am Acad Dermatol · 2021-01-23

该研究基于488例原发性基底细胞癌(BCC)队列,开发布莱根妇女医院(BWH)T分期系统,并与AJCC第8版T分期比较预测转移/死亡的表现。BWH与AJCC8在高分期均捕获全部转移/死亡,但BWH T2纳入的≥2 cm病例比AJCC8 T3/T4少54%,特异度(0.92 vs 0.80,P < .001)与阳性预测值(24% vs 11%,P < .001)更高,C统计量更优(P < .001)。BWH T2的10年转移/死亡累积发生率为37%(95%CI 21%-60%)。

要点

  • BWH与AJCC8高分期均捕获全部转移/死亡,但BWH所需病例数约减半。
  • BWH T2识别转移/死亡风险的特异度和阳性预测值均显著优于AJCC8 T3/T4。
  • BWH T2的10年转移/死亡累积发生率为37%,足以支持复发监测与辅助治疗临床试验。

核心结论

  • BWH与AJCC8 T分期均能在高分期捕获全部转移和死亡,但BWH以约一半的病例数实现,减少不适当的上分期。
  • BWH T2 BCC的转移或死亡风险足以支持复发监测和辅助治疗临床试验。

研究设计与样本

  • BWH T分期系统基于既往发表的488例原发性BCC嵌套队列开发。
  • 肿瘤分别按BWH与AJCC8 T分期系统进行分期,并比较对转移和/或死亡的预测表现。
  • 研究为两中心队列。

主要发现

  • BWH与AJCC8 T分期均在高T分期(BWH为T2;AJCC8为T3/T4)捕获全部转移/死亡。
  • BWH T2纳入的≥2 cm病例比AJCC8 T3/T4少54%。
  • BWH识别转移/死亡风险的特异度为0.92,AJCC8为0.80(P < .001)。
  • BWH阳性预测值为24%,AJCC8为11%(P < .001);BWH的C统计量更优(P < .001)。
  • BWH T2的10年转移/死亡累积发生率为37%(95%CI 21%-60%)。

关键数值与推荐

  • BWH高分期为T2,AJCC8高分期为T3/T4,两者均捕获全部转移/死亡。
  • BWH T2中≥2 cm病例数比AJCC8 T3/T4少54%。
  • BWH特异度0.92 vs AJCC8 0.80(P < .001);阳性预测值24% vs 11%(P < .001)。
  • BWH T2的10年转移/死亡累积发生率为37%(95%CI 21%-60%)。

临床怎么用

  • 可采用BWH T分期识别BCC转移/死亡高风险患者,同时减少不适当上分期。
  • 对BWH T2患者应考虑复发监测,并可纳入辅助治疗临床试验。

局限性

  • 研究为两中心队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite approximately 4400 locally advanced US cases annually, high-stage basal cell carcinoma (BCC) is ill-defined. OBJECTIVE: To develop a tumor (T) staging system for BCC that will predict metastasis/death and compare its performance with that of the American Joint Committee on Cancer 8th edition (AJCC8) T-staging system. METHODS: Brigham and Women's Hospital (BWH) T staging was developed from a previously published nested cohort of 488 primary BCCs. Tumors were staged via BWH and AJCC8 T-staging systems, and predictions of metastasis and/or death were compared. RESULTS: The BWH and AJCC8 T-staging systems both captured all metastases/deaths in high T stages (BWH, T2; AJCC8, T3/T4). BWH T2 included 54% fewer cases ≥2 cm than AJCC8 T3/T4. BWH had a higher specificity (0.92 vs 0.80; P < .001) and positive predictive value (24% vs 11%, P < .001) for identifying cases at risk for metastasis/death, and the C-statistic was superior for BWH (P < .001). The BWH T2 10-year cumulative incidence of metastasis/death was 37% (95% confidence interval, 21%-60%). LIMITATIONS: Two-center cohort. CONCLUSIONS: BWH and AJCC 8 BCC staging both capture all metastases and deaths in the upper stages. However, BWH staging does so in half the number of cases, thus minimizing inappropriate up-staging. The risk of metastasis or death in BWH T2 BCC is sufficient to warrant surveillance for recurrence and clinical trials of adjuvant therapy.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Morgan FC, Ruiz ES, Karia PS, et al. Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death. J Am Acad Dermatol. 2021. PMID: 33497751. doi:10.1016/j.jaad.2021.01.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。